At Lexicon, we're committed to pioneering treatments that transform lives and promote healthier futures for all. Visit our website to learn more about us and our latest news: lexpharma.com

We’re in NYC on May 20 for the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference. Find details of our presentation on our Investors page: investors.lexpharma.com/news-events/ev… #HCWBioConnect

Following #PeripheralNeuropathyAwarenessWeek, let’s continue to shine a light on #DPNP, which impacts 25% of people with diabetes. Despite the prevalence, treatment options are limited. At Lexicon, we're committed to transforming pain management for better lives.

Yesterday, Lexicon announced its Q1 2025 financial results. Find our business updates here: investors.lexpharma.com/news-releases/…

Excited to attend the AACE Annual Meeting this week! We’re looking forward to connecting with others in the endocrinology community advancing care for those with diabetes and related disorders, and obesity. #AACE2025

On Saturday, Lexicon presented details of our Phase 3 SONATA-HCM study design at the European Society of Cardiology Heart Failure 2025 Congress. Learn more about our clinical HCM program: investors.lexpharma.com/news-releases/… #HeartFailure2025

Did you know that HCM can affect people of any age? Together, we can make a difference by raising awareness and advocating for better heart health.

Lexicon returns to NYC for a fireside chat at the Jefferies Global Healthcare Conference! Catch the live event on June 5 at 12:50pm ET or watch the replay on our Events page: investors.lexpharma.com/news-events/ev… #JefferiesHealthcare

Lexicon is excited to attend this week’s American Diabetes Association 2025 Scientific Sessions to discuss the latest in diabetes care with those across the research and clinical community. Read more in today’s press release: investors.lexpharma.com/news-releases/… #ADASciSessions

This weekend, Belinda Hardin, PharmD, presented data on our SGLT1/SGLT2 inhibitor at the American Diabetes Association - DiabetesPro 2025 Scientific Sessions. Discover more in our press release: investors.lexpharma.com/news-releases/…

Grateful to have joined TCOYD & The diaTribe Foundation at the recent #ADASciSessions. Thank you for empowering, educating, and advocating for patients and their families.

Diabetic peripheral neuropathy (DPN) affects nerves in the legs, feet, hands, and arms, causing pain and mobility issues. Current therapies often fall short. At Lexicon, we're dedicated to advancing a new, non-opioid treatment. #DiabeticPeripheralNeuropathy

Our Sr. Medical Director, Belinda Hardin, PharmD, recently spoke with Managed Healthcare on a recently presented analysis regarding the risks of hypoglycemia for individuals living with Type 1 diabetes. Read here: managedhealthcareexecutive.com/preview/766640…

Lexicon recently attended the ASPN 2025 Congress, presenting a poster on the patient experience of diabetic peripheral neuropathic pain (DPNP).

On August 6, Lexicon will report our second quarter financial results along with a comprehensive business update. Conference call details can be found here: investors.lexpharma.com/news-releases/…

Diabetic peripheral neuropathy affects millions, causing pain in legs, feet, hands, and arms. Despite rising cases, no new pain therapies have emerged in 20+ years. Lexicon aims to change this with a novel, non-opioid therapy targeting pain signaling. #LearnWithLexicon

We had an amazing weekend at the ASPC conference! We were proud to sponsor this event and engage with leaders at the forefront of advancing care for those with cardiovascular disease. #ASPC2025

Today, Lexicon announced its Q2 2025 financial results. Find our business updates here: investors.lexpharma.com/news-releases/…

We had an amazing time at TCOYD’s ONE 2025 Conference! Each year we leave more inspired than ever by this vibrant community.

Hypertrophic Cardiomyopathy (HCM) affects an estimated 1.1 million Americans. Despite treatment progress, there’s still a need for better management, and we’re committed to developing a potential therapy to improve patient care.  #LearnwithLexicon